Related Experiment Videos
[Modification of atrial natriuretic peptide (ANP) and cyclic GMP by hemofiltration and hemodialysis]
T Eisenhauer1, J Talartschik, E Quentin
1Abteilung Nephrologie und Rheumatologia, Medizinische Universitätsklinik Göttingen.
Insights
This study found that both hemofiltration and hemodialysis equally affect atrial natriuretic peptide (ANP) and cyclic guanosine monophosphate (cGMP) levels in chronic renal failure (CRF) patients. ANP levels may help monitor fluid status in dialysis patients.
Area of Science:
- Nephrology
- Cardiovascular Physiology
Background:
- Chronic renal failure (CRF) impacts fluid balance and cardiovascular regulation.
- Atrial natriuretic peptide (ANP) and cyclic guanosine monophosphate (cGMP) are key regulators of fluid and electrolyte homeostasis.
Purpose of the Study:
- To compare ANP and c-GMP levels in CRF patients undergoing hemofiltration (HF) versus hemodialysis (HD).
- To assess the impact of dialysis modality on ANP and c-GMP profiles.
- To evaluate the diagnostic utility of ANP in monitoring fluid status during dialysis.
Main Methods:
- Measured ANP and c-GMP concentrations in 7 CRF patients.
- Compared levels during HF and HD with identical ultrafiltration and treatment times.
- Observed hormonal responses to physiological challenges like hypotension and tachyarrhythmia during HD.
Main Results:
- No significant difference in ANP and c-GMP profiles was observed between HF and HD.
- Both treatments showed a continuous decrease in ANP and c-GMP.
- Hypotension and tachyarrhythmia during HD triggered increases in ANP and c-GMP.
- ANP secretion was not found to be altered in CRF patients.
Conclusions:
- Dialysis modality (HF vs. HD) does not significantly affect ANP and c-GMP plasma levels.
- ANP plasma levels correlate with intravascular volume, suggesting its potential for monitoring fluid overload in dialysis patients.
- Periodic ANP determination can aid in managing fluid balance for patients on hemodialysis or hemofiltration.
Abstract:
ANP and c-GMP concentrations in 7 patients with chronic renal failure (CRF) undergoing regular hemofiltration (HF) were determined. After switching to hemodialysis (HD) under identical ultrafiltration and treatment time no significant difference of the ANP and c-GMP profiles was detected, suggesting that the type of treatment does not affect ANP and c-GMP plasma levels. In both procedures a continuous decrease of ANP and c-GMP was observed. Head down tilting to compensate hypotension during HD was immediately followed by an increase in ANP and c-GMP during ultrafiltration. An acute onset of tachyarrhythmia absoluta during HD was also accompanied by a rise in ANP plasma concentrations. This demonstrates that ANP secretion is not altered in patients with CRF. Since ANP plasma levels closely correlate with intravascular volume, periodic determination of this hormone in HD/HF patients may provide diagnostic information to detect volume overload.